You are here

Cara Fraley

Publications

Garvie CW, Fraley CV, Elowe NH, et al. Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. Protein Sci. 2016, Nov 25 (11):2018-2027.

 D, Reidy T, McCue J, Franck HW, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood. 2012 Mar 29;119(13):3024-30. 

Wang Z, Fraley C, Mezo AR. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1253-6. 

Dumont JA, Liu T, Low SC, Zhang X, Kamphaus G, Sakorafas P, Fraley C, Drager
Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, Bitonti AJ. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2337-42.
 
Mezo AR, McDonnell KA, Castro A, Fraley C. Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405. 

Cara Fraley, M.S.

Cara Fraley is a research scientist I in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard under the direction of Colin Garvie. She is part of a team that carries out drug discovery campaigns based on genetic and phenotypic targets identified by Broad’s academic labs and screening platforms. 

Fraley joined the Broad Institute in August 2012 as a senior research associate and transitioned into her current post in January 2018. She previously worked as a senior associate scientist for Biogen Idec/Syntonix Pharmaceuticals performing assay development for several successful programs including the long lasting hemophilia drugs Alprolix and Eloctate. Prior to Biogen, Fraley worked at the Faculte de Pharmacie in Illkirch, France, where she studied GPCRs and spent her free time sampling Alsatian wines and cheeses. Fraley began her career at a small startup, Mosaic Technologies, performing assay development on a technology that was later sold to Exact Sciences and evolved into their Cologuard diagnostic test for colon cancer screening.

Fraley has an M.S. in biochemistry from Boston College and a B.S. in chemistry from Seton Hall University.  

Contact Cara Fraley via email at cfraley@broadinstitute.org.

January 2021